Timoptic®
Timolol Maleate 0.25% or 0.5% · preservative-free ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in ocular hypertension or open-angle glaucoma
1 drop of 0.25% BID, increased to 1 drop of 0.5% BID if response is inadequate, and reducible to 1 drop QD once IOP is controlled
IOP falls within half an hour, peaks at 1 to 2 hours, and lowering can persist for 24 hours.
OFF-LABELNot in the FDA label for this product
Periocular and cutaneous infantile hemangioma
Timolol maleate solution 0.5% applied to the lesion BID for 24 weeks (trial regimen)
RCT · n=69 · no benefit
A multicenter double-blind placebo-controlled phase 2a trial in 69 infants aged 10 to 60 days found no significant difference in complete or nearly complete resolution at 24 weeks (42% vs 36%, P=.37; OR 1.33, 95% CI 0.45 to 3.89) and no between-group difference in lesion volume or thickness, with color improvement at week 4 and no systemic adverse effects; the authors concluded benefit is limited when treatment starts in the early proliferative stage. Periocular-specific experience is limited to small retrospective series.
Contraindications
- Bronchial asthma or a history of bronchial asthma.
- Severe chronic obstructive pulmonary disease.
- Sinus bradycardia.
- Second or third degree atrioventricular block.
- Overt cardiac failure.
- Cardiogenic shock.
- Hypersensitivity to any component of this product.
0.25% and 0.5% preservative-free solution, 0.3 mL single-dose vials, 60 vials per carton
Non-selective beta-1 and beta-2 adrenergic blocker with no significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Lowers elevated and normal IOP; the precise mechanism is not clearly established, but tonography and fluorophotometry studies suggest the predominant action may be related to reduced aqueous formation, with a slight increase in outflow facility in some studies.
Warnings & Precautions
- Severe respiratory and cardiac reactions: This drug is absorbed systemically, and the same adverse reactions found with systemic beta-blockers may occur with topical administration; death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure have been reported.
- Cardiac failure: Beta-adrenergic receptor blockade may precipitate more severe failure in individuals with diminished myocardial contractility. In patients without a history of cardiac failure, continued depression of the myocardium over a period of time can, in some cases, lead to cardiac failure; discontinue at the first sign or symptom of cardiac failure.
- Obstructive pulmonary disease: Patients with chronic obstructive pulmonary disease of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, which are contraindications) should, in general, not receive beta-blockers.
- Protracted severe hypotension during anesthesia: Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli and may augment the risk of general anesthesia; difficulty in restarting and maintaining the heartbeat has also been reported. Withdrawal before major surgery is controversial; some authorities recommend gradual withdrawal before elective surgery, and the effects may be reversed by sufficient doses of adrenergic agonists if necessary.
- Masked symptoms of hypoglycemia: Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia; use with caution in patients subject to spontaneous hypoglycemia and in diabetic patients (especially those with labile diabetes) receiving insulin or oral hypoglycemic agents.
- Thyroid storm: Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism; manage patients suspected of developing thyrotoxicosis carefully to avoid abrupt withdrawal, which might precipitate a thyroid storm.
- Anaphylaxis: Patients with atopy or prior severe anaphylaxis may be more reactive on re-challenge and unresponsive to usual epinephrine doses.
- Muscle weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness), and timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.
- Angle-closure glaucoma: Little or no effect on the pupil, so not for use alone in angle closure.
- Choroidal detachment: Reported with aqueous suppressant therapy after filtration procedures.
- Reduced cerebral blood flow: Because of potential effects on blood pressure and pulse, use with caution in patients with cerebrovascular insufficiency; if signs or symptoms suggesting reduced cerebral blood flow develop after starting therapy, consider alternative therapy.
- Additive effects of beta-blockade: Observe patients also receiving an oral beta-blocker for additive effects, both systemic and on intraocular pressure; the concomitant use of two topical beta-adrenergic blocking agents is not recommended. Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported with CYP2D6 inhibitors (e.g., quinidine, SSRIs).
- Atrioventricular conduction disturbances: Use caution when giving oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension, and avoid coadministration in patients with impaired cardiac function. Concomitant use with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
- Hypotension and marked bradycardia: Close observation is recommended with catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
Common Side Effects
The most frequently reported adverse experiences have been burning and stinging upon instillation, in approximately one in eight patients. Less frequent ocular reactions include conjunctivitis, blepharitis, keratitis, decreased corneal sensitivity, dry eyes, ptosis, cystoid macular edema, pseudopemphigoid, and choroidal detachment following filtration surgery. Less frequent systemic reactions include bradycardia, arrhythmia, hypotension, heart block, syncope, cardiac failure, cardiac arrest, bronchospasm (predominantly in patients with pre-existing bronchospastic disease), dyspnea, headache, dizziness, depression, and increased signs and symptoms of myasthenia gravis. A slight reduction of resting heart rate in some patients (mean reduction 2.9 beats/minute, standard deviation 10.2) was observed in controlled studies.
Pregnancy: No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk (animal studies showed no malformations but increased fetal resorptions at high multiples of the ophthalmic dose).
Lactation: Timolol has been detected in human milk after oral and ophthalmic dosing; because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness established at 2 years and older; not established below 2 years.